Several studies demonstrate that extracorporeal stimulation of autologous Natural Killer (NK) cells with Interleukin-2 (IL-2) in conjunction with adoptive transfer and subcutaneous IL-2 infusions increased overall survival (OS) in a subset of patients with advanced cancers (70). The gene discussed is IL2; the disease is cancer.